US FDA APPROVES BYDUREON® PEN (EXENATIDE EXTENDED-RELEASE FOR INJECTABLE SUSPENSION) FOR ONCE-WEEKLY TREATMENT OF ADULTS with TYPE 2 DIABETES AstraZeneca today announced that the US Food and Drug ...

FDA approves the extended-release Bydureon Pen for the treatment of type 2 diabetes. FDA approved the Bydureon Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and ...

AstraZeneca ($AZN) won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The ...

With a view to improve treatment for diabetes patients through innovative technology, product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon ...

US regulators have given the thumbs-up to AstraZeneca's pre-filled, single-use pen injector version of its long-acting diabetes drug Bydureon. US regulators have given the thumbs-up to AstraZeneca’s ...

If you have type 2 diabetes, your doctor may recommend Bydureon BCise as a treatment. It’s used with a balanced diet and exercise to help manage blood sugar. Bydureon BCise is used in adults and ...

WILMINGTON, Del. — AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an ...

AstraZeneca has received regulatory approval for a single-use pen injector to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence rates and a huge unmet ...

AstraZeneca has launched in the UK a new pre-filled pen containing its once-weekly diabetes drug Bydureon (exenatide), offering patients a simpler route of administration. AstraZeneca has launched in ...

The US Food and Drug Administration (FDA) has approved extended-release exenatide in a pen form for the treatment of adults with type 2 diabetes, according to the manufacturer. AstraZeneca's exenatide ...

WILMINGTON, Del. -- AstraZeneca has received regulatory approval for a single-use pen injector designed to improve glycemic control in patients with type 2 diabetes – a disease with soaring prevalence ...